AB189891

Anti-ENO1 + ENO2 + ENO3 antibody [EPR18407]

RabMAb
Recombinant
What is this?

Be the first to review this product! Submit a review

(2 Publications)

Rabbit Recombinant Monoclonal ENO1 antibody. Suitable for WB, ICC/IF, Flow Cyt (Intra) and reacts with Recombinant full length protein - Human, Mouse, Rat, Human samples. Cited in 2 publications.

View Alternative Names

ENO1L1, MBPB1, MPB1, ENO1, Alpha-enolase, 2-phospho-D-glycerate hydro-lyase, C-myc promoter-binding protein, Enolase 1, MBP-1, MPB-1, Non-neural enolase, Phosphopyruvate hydratase, Plasminogen-binding protein, NNE, Gamma-enolase, 2-phospho-D-glycerate hydro-lyase, Enolase 2, Neural enolase, Neuron-specific enolase, NSE, ENO2, Beta-enolase, 2-phospho-D-glycerate hydro-lyase, Enolase 3, Muscle-specific enolase, Skeletal muscle enolase, MSE, ENO3

7 Images

Immunocytochemistry/ Immunofluorescence - Anti-ENO1 + ENO2 + ENO3 antibody [EPR18407] (AB189891)

ICC/IF

Supplier Data

Immunocytochemistry/ Immunofluorescence - Anti-ENO1 + ENO2 + ENO3 antibody [EPR18407] (AB189891)

Immunofluorescent analysis of 4% paraformaldehyde-fixed 0.1% Triton X-100 permeabilized HeLa (Human epithelial cell line from cervix adenocarcinoma) cells labeling ENO1 + ENO2 + ENO3 with ab189891 at 1/500 dilution followed by Goat Anti-Rabbit IgG (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution (green).

Confocal image showing mostly cytoplasmic staining on Hela cells.

The nuclear counterstain is DAPI (blue).

Tubulin is detected with Anti-alpha Tubulin - Loading Control (ab7291) at 1/1000 dilution and Goat Anti-Mouse IgG (AlexaFluor®594) preadsorbed (ab150120) at 1/1000 dilution (red).

The negative controls are as follows : -

-ve control 1 : ab189891 at 1/500 dilution followed by ab150120 at 1/1000 dilution.

-ve control 2 : ab7291 at 1/1000 dilution followed by ab150077 at 1/1000 dilution.

Flow Cytometry (Intracellular) - Anti-ENO1 + ENO2 + ENO3 antibody [EPR18407] (AB189891)

Flow Cyt (Intra)

Supplier Data

Flow Cytometry (Intracellular) - Anti-ENO1 + ENO2 + ENO3 antibody [EPR18407] (AB189891)

Intracellular flow cytometric analysis of 4% paraformaldehyde-fixed NIH/3T3 (Mouse embryonic fibroblast cell line) labeling ENO1 + ENO2 + ENO3 with ab189891 at 1/70 dilution (red) compared with a Rabbit IgG,monoclonal- Isotype control (ab172730) (black) and an unlabelled control (cells without incubation with primary antibody and secondary antibody) (blue). Goat anti Rabbit IgG (Alexa Fluor^® 488) at 1/500 dilution was used as the secondary antibody.

ICC/IF

Supplier Data

Immunocytochemistry/ Immunofluorescence - Anti-ENO1 + ENO2 + ENO3 antibody [EPR18407] (AB189891)

Immunofluorescent analysis of 4% paraformaldehyde-fixed 0.1% Triton X-100 permeabilized NIH/3T3 (Mouse embryonic fibroblast cell line) cells labeling ENO1 + ENO2 + ENO3 with ab189891 at 1/500 dilution followed by Goat Anti-Rabbit IgG (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution (green).

Confocal image showing mostly cytoplasmic staining on NIH/3T3 cells.

The nuclear counterstain is DAPI (blue).

Tubulin is detected with Anti-alpha Tubulin antibody -Loading Control (ab7291) at 1/1000 dilution and Goat Anti-Mouse IgG (AlexaFluor®594) preadsorbed (ab150120) at 1/1000 dilution (red).

The negative controls are as follows : -

-ve control 1 : ab189891 at 1/500 dilution followed by ab150120 at 1/1000 dilution.

-ve control 2 : ab7291 at 1/1000 dilution followed by ab150077 at 1/1000 dilution.

Supplier Data

Western blot - Anti-ENO1 + ENO2 + ENO3 antibody [EPR18407] (AB189891)

Blocking/Dilution buffer : 5% NFDM/TBST.

Human ENO1 full length recombinant protein (Cat# : ab89248) contains aa1-434. Human ENO2 full length recombinant protein contains aa1-434 with a His-Tag®. Human ENO3 full length recombinant protein(Cat# : ab113127) contains aa1-434 with a His-Tag®. Human ENO2 full length recombinant protein was made in-house.

All lanes:

Western blot - Anti-ENO1 + ENO2 + ENO3 antibody [EPR18407] (ab189891) at 1/1000 dilution

Lane 1:

Human ENO1 full length recombinant protein at 0.02 µg

Lane 2:

Human ENO2 full length recombinant protein at 0.02 µg

Lane 3:

Human ENO3 full length recombinant protein at 0.02 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution

Predicted band size: 47 kDa

Observed band size: 47 kDa

false

Exposure time: 5s

Supplier Data

Western blot - Anti-ENO1 + ENO2 + ENO3 antibody [EPR18407] (AB189891)

Blocking/Dilution buffer : 5% NFDM/TBST.

Exposure time : Lane 1 and 2 : 5 seconds; Lane 3 : 15 seconds.

All lanes:

Western blot - Anti-ENO1 + ENO2 + ENO3 antibody [EPR18407] (ab189891) at 1/1000 dilution

Lane 1:

Human fetal heart lysate at 10 µg

Lane 2:

Human fetal kidney lysate at 10 µg

Lane 3:

Human fetal spleen lysate at 10 µg

Secondary

All lanes:

Goat Anti-Rabbit IgG Peroxidase Conjugate, specific to the non-reduced form of IgG at 1/10000 dilution

Predicted band size: 47 kDa

Observed band size: 47 kDa

false

Supplier Data

Western blot - Anti-ENO1 + ENO2 + ENO3 antibody [EPR18407] (AB189891)

Blocking/Dilution buffer : 5% NFDM/TBST.

All lanes:

Western blot - Anti-ENO1 + ENO2 + ENO3 antibody [EPR18407] (ab189891) at 1/5000 dilution

Lane 1:

HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate at 20 µg

Lane 2:

Jurkat (Human T cell leukemia cell line from peripheral blood) whole cell lysate at 20 µg

Lane 3:

MCF7 (Human breast adenocarcinoma cell line) whole cell lysate at 20 µg

Lane 4:

A431 (Human epidermoid carcinoma cell line) whole cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution

Predicted band size: 47 kDa

Observed band size: 47 kDa

false

Exposure time: 3s

Supplier Data

Western blot - Anti-ENO1 + ENO2 + ENO3 antibody [EPR18407] (AB189891)

Blocking/Dilution buffer : 5% NFDM/TBST.

Exposure time : Lane 1-4 : 5 seconds; Lane 5-7 : 1 second.

Lanes 1 - 4:

Western blot - Anti-ENO1 + ENO2 + ENO3 antibody [EPR18407] (ab189891) at 1/1000 dilution

Lanes 5 - 7:

Western blot - Anti-ENO1 + ENO2 + ENO3 antibody [EPR18407] (ab189891) at 1/5000 dilution

Lane 1:

Mouse brain tissue lysate at 10 µg

Lane 2:

Mouse heart tissue lysate at 10 µg

Lane 3:

Rat brain tissue lysate at 10 µg

Lane 4:

Rat heart tissue lysate at 10 µg

Lane 5:

C6 (Rat glial tumor cell line) whole cell lysate at 10 µg

Lane 6:

RAW 264.7 (Mouse macrophage cell line transformed with Abelson murine leukemia virus) whole cell lysate at 10 µg

Lane 7:

NIH/3T3 (Mouse embryonic fibroblast cell line) whole cell lysate at 10 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/10000 dilution

Predicted band size: 47 kDa

Observed band size: 47 kDa

false

Carrier free

Anti-ENO1 + ENO2 + ENO3 antibody [EPR18407] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR18407

Isotype

IgG

Carrier free

Reacts with

Mouse, Rat, Human

Applications

Flow Cyt (Intra), WB, ICC/IF

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

style

left-column

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "FlowCytIntra" : {"fullname" : "Flow Cytometry (Intracellular)", "shortname":"Flow Cyt (Intra)"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/500", "ICCIF-species-notes": "", "FlowCytIntra-species-checked": "guaranteed", "FlowCytIntra-species-dilution-info": "", "FlowCytIntra-species-notes": "" }, "Mouse": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/500", "ICCIF-species-notes": "", "FlowCytIntra-species-checked": "testedAndGuaranteed", "FlowCytIntra-species-dilution-info": "1/70", "FlowCytIntra-species-notes": "" }, "Rat": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "", "ICCIF-species-checked": "guaranteed", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "FlowCytIntra-species-checked": "guaranteed", "FlowCytIntra-species-dilution-info": "", "FlowCytIntra-species-notes": "" }, "Recombinant full length protein - Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "FlowCytIntra-species-checked": "notRecommended", "FlowCytIntra-species-dilution-info": "", "FlowCytIntra-species-notes": "" } } }

style

left-column

Product details

Patented technology
Our RabMAb^® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb^® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

style

left-column

Properties and storage information

Form

Liquid

Purification technique

Affinity purification Protein A

Storage buffer

pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA

Shipped at conditions

Conditional Ambient

Appropriate short-term storage duration

1-2 weeks

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Aliquoting information

Upon delivery aliquot

Storage information

Avoid freeze / thaw cycle

style

left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

ENO1 ENO2 and ENO3 also known as alpha gamma and beta enolase are isoenzymes involved in the glycolytic pathway. Each enolase isoenzyme offers specific mechanical functions in this energy-producing process. ENO1 has an approximate mass of 47 kDa and is widely expressed in most tissues. ENO2 similar in size is primarily found in neural and neuroendocrine tissues. ENO3 also roughly 47 kDa predominantly expresses in muscle tissue. These proteins catalyze the reversible conversion of 2-phosphoglycerate to phosphoenolpyruvate playing an important role in glycolysis.

Biological function summary

The enolase family of isoenzymes acts as multifunctional catalysts and has roles beyond glycolysis. ENO1 serves as a plasminogen receptor on cell surfaces assisting in tissue remodeling and immune response. ENO2 often referred to as neuron-specific enolase (NSE) functions importantly in neural development and tumor cell metabolism. ENO3 or muscle-specific enolase contributes to muscle metabolism and energy turnover. While these proteins individually carry out essential tasks they also form a complex that facilitates efficient energy production and cellular regulation.

Pathways

The enolase enzymes integrate in the glycolytic and gluconeogenesis pathways central to energy metabolism. Glycolysis involves other key proteins like hexokinase and phosphofructokinase cooperating for glucose breakdown and energy release. In gluconeogenesis the enolases help generate glucose from non-carbohydrate sources important during fasting or intense exercise. Their activity along with related proteins impacts the efficiency and regulation of energy metabolism pathways.

Enolase dysregulation associates with conditions like cancer and neuromuscular diseases. Elevated ENO2 levels often serve as a biomarker for neuroendocrine tumors and a target for cancer therapies. ENO3 mutations link to muscle metabolic disorders including glycogen storage diseases. ENO1 interaction with proteins such as plasminogen can influence cancer cell invasion and metastasis highlighting its relevance in disease progression and potential therapeutic interventions.

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

Enolase that catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate in glycolysis and the reverse reaction in gluconeogenesis (PubMed : 1369209, PubMed : 29775581). Also involved in various processes such as growth control, hypoxia tolerance and allergic responses (PubMed : 10802057, PubMed : 12666133, PubMed : 2005901, PubMed : 29775581). May also function in the intravascular and pericellular fibrinolytic system due to its ability to serve as a receptor and activator of plasminogen on the cell surface of several cell-types such as leukocytes and neurons (PubMed : 12666133). Stimulates immunoglobulin production (PubMed : 1369209).. Isoform MBP-1. Binds to the myc promoter and acts as a transcriptional repressor. May be a tumor suppressor.

See full target information ENO1

Additional targets

ENO2,ENO3

style

left-column

Publications (2)

Recent publications for all applications. Explore the full list and refine your search

Oncology letters 19:2846-2860 PubMed32218839

2020

Identification of hub genes associated with outcome of clear cell renal cell carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Rengui Li,Lei Wang,Xiao Wang,Rong-Xin Geng,Ning Li,Xiu-Heng Liu

PloS one 11:e0168739 PubMed28030597

2016

ENOblock Does Not Inhibit the Activity of the Glycolytic Enzyme Enolase.

Applications

Unspecified application

Species

Unspecified reactive species

Nikunj Satani,Yu-Hsi Lin,Naima Hammoudi,Sudhir Raghavan,Dimitra K Georgiou,Florian L Muller

View all publications

style

left-column

style

left-column

style

right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.

For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-ENO1 + ENO2 + ENO3 antibody [EPR18407]

Immunocytochemistry/ Immunofluorescence - Anti-ENO1 + ENO2 + ENO3 antibody [EPR18407] (AB189891)

Flow Cytometry (Intracellular) - Anti-ENO1 + ENO2 + ENO3 antibody [EPR18407] (AB189891)

Immunocytochemistry/ Immunofluorescence - Anti-ENO1 + ENO2 + ENO3 antibody [EPR18407] (AB189891)

Western blot - Anti-ENO1 + ENO2 + ENO3 antibody [EPR18407] (AB189891)

Western blot - Anti-ENO1 + ENO2 + ENO3 antibody [EPR18407] (AB189891)

Western blot - Anti-ENO1 + ENO2 + ENO3 antibody [EPR18407] (AB189891)

Western blot - Anti-ENO1 + ENO2 + ENO3 antibody [EPR18407] (AB189891)

Related conjugates and formulations (1)

Key facts

Host species

Clonality

Clone number

Isotype

Carrier free

Reacts with

Applications

Immunogen

Alternative Products

Primary Antibodies

Primary Antibodies

Complementary Products

Assay Kits

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Reactivity data

Product details

Properties and storage information

Form

Purification technique

Storage buffer

Shipped at conditions

Appropriate short-term storage duration

Appropriate short-term storage conditions

Appropriate long-term storage conditions

Aliquoting information

Storage information

Supplementary information

Biological function summary

Pathways

Product protocols

Target data

Additional targets

Publications (2)

Product promise